Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA
Published Time:
2024-10-17 17:29
Source:
On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone, obtaining Investigational New Drug (IND) approval from the US FDA. This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and successful execution of the company's strategies centered on original innovation, high-quality standards, and a global layout.
The TRK gene fusion plays a key role in various cancers and is one of the important driving factors for cancer occurrence and development. Clinically, VC004 is primarily used to treat patients with NTRK gene fusion-positive tumors and is not limited to specific cancer types. As a new-generation TRK inhibitor, VC004 has demonstrated excellent efficacy and safety in multiple previous clinical studies in China. It is currently in the subject follow-up and pre-New Drug Application (NDA) preparation stage.
VC004 not only shows a higher clinical response rate compared with first-generation drugs but also exhibits significant anti-resistance to first-generation drugs. The previous clinical data were impressively presented at the 2024 American Society of Clinical Oncology (ASCO 2024) annual meeting: among patients who have not been treated with TRK TKI previously, the confirmed objective response rate (ORR) in the recommended phase 2 dose (RP2D) expansion group is 73.1% [95% CI, 52.2-88.4]; among 3 patients who have progressed after being treated with TRK-TKIs previously, the tumors of 2 patients have shrunk, and 1 patients has achieved a partial response (PR) (39.6%); for the vast majority of patients after treatment with VC004, the drug takes effect quickly and they obtain long-term survival benefits, and the longest duration of continuous remission of patients has exceeded 36 months; among 6 patients with baseline brain metastases, the intracranial lesions of 2 patients have shrunk by 61.8% and 25% respectively, and the non-target lesions of another 2 patients have disappeared after 4 months of treatment. In terms of safety, most treatment-related adverse events (TRAEs) that patients experienced are grade 1-2, and no fatal TRAEs have occurred. Compared with other drugs of the same kind, no new safety signals have been found.
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn